TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study published in Nature Communications reports that elevated Miro1 in skeletal muscle is linked to insulin resistance in type 2 diabetes. Removing the protein restored insulin response in preclinical models, while an exercise group in a trial had lower muscle Miro1 levels and improved insulin sensitivity. The findings do not establish a Miro1-based treatment for people.
A study published October 19 in Nature Communications links elevated levels of the mitochondrial protein Miro1 in skeletal muscle to insulin resistance in people with type 2 diabetes. Researchers reported that removing Miro1 restored muscle response to insulin in preclinical models, while participants with obesity and type 2 diabetes who took part in an aerobic exercise group had lower muscle Miro1 levels and improved insulin sensitivity; the findings do not show that targeting the protein is an established treatment.
The researchers examined Miro1, or Mitochondrial Rho GTPase 1, across cells, preclinical models and people with type 2 diabetes. The protein is located on the outer membrane of mitochondria, the structures within cells that produce energy. The study, led by senior author John P. Kirwan, investigated how Miro1 relates to muscle function and the muscle’s response to insulin.
According to the report, the team found that Miro1 accumulation impaired insulin response in muscle. Removing the protein restored that response in the preclinical models. That result supports a causal role within those models, but it does not establish that removing or blocking Miro1 would safely or effectively improve blood sugar control in people.
The human findings came from a randomized controlled trial involving people with obesity and type 2 diabetes. Researchers compared aerobic exercise with standard medical care. The exercise group had reductions in muscle Miro1, alongside improvements in insulin sensitivity and the muscles’ ability to produce energy. The report does not provide the number of participants or the size of these changes, so their scale cannot be assessed from the supplied findings.
A Muscle Pathway for Insulin Resistance
Skeletal muscle plays a major role in the body’s response to insulin. A finding that connects Miro1 buildup with impaired muscle insulin response may help researchers investigate one mechanism behind insulin resistance, a feature of type 2 diabetes. The study’s combination of laboratory work, preclinical models and human observations provides several lines of evidence, though each supports a different level of conclusion.
The exercise results also offer a possible molecular link between physical activity and improved insulin sensitivity in the study participants: exercise coincided with lower Miro1 levels in muscle. They do not show that the Miro1 change alone caused the improvement, or that manipulating the protein would reproduce exercise’s effects. Kirwan described Miro1 as a potential therapeutic target, but the report says further research is needed before that possibility could translate into treatment.
For readers, the distinction is important. These are findings about a biological mechanism and a potential research direction, not evidence that an experimental Miro1-targeting approach is available or that people should change diabetes care. Medical decisions should be discussed with a qualified health professional.
muscle insulin sensitivity supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Pennington Research to OU
The work was conducted while Kirwan was at Pennington Biomedical Research Center. He has since been named executive director of the OU Health Harold Hamm Diabetes Center at the University of Oklahoma, where he is expected to continue translational research connecting laboratory studies with research in people. First author Elizabeth Heintz was a doctoral candidate in Pennington Biomedical’s Integrated Physiology and Molecular Medicine Laboratory; co-corresponding author Christopher Axelrod has also joined Kirwan at the center.
The article is titled Miro1 mediates skeletal muscle insulin resistance in type 2 diabetes and appeared in Nature Communications. Its stated approach spans cells, preclinical models and people, allowing the researchers to examine Miro1’s effects at different levels. The report presents the results as a foundation for further study, not as a completed clinical test of a new therapy.
““Miro1 accumulation impairs the muscle’s response to insulin, that removing it causally restores that response in our models, and that exercise reverses its buildup in people.””
— Dr. John P. Kirwan, senior author
As an affiliate, we earn on qualifying purchases.
Treatment Potential Still Unproven
The supplied report does not state how many people took part in the exercise trial, the duration of the intervention, or the size of the Miro1 and insulin-sensitivity changes. Those details are needed to judge the scope and practical significance of the human results. It is also unclear whether the Miro1 reduction itself contributed to improved insulin sensitivity or occurred alongside other exercise-related changes.
Most importantly, the reported restoration of insulin response after Miro1 removal was in preclinical models. The findings do not establish that a drug or other intervention targeting Miro1 would work in people, what its risks might be, or whether it would improve clinical outcomes. The report gives no timeline for human trials of a Miro1-targeting treatment.
exercise equipment for diabetes management
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Work on Miro1
The researchers say more research is needed to determine whether targeting Miro1 could lead to new treatments. Follow-up work would need to clarify how Miro1 affects muscle insulin response, test whether those effects hold across further models and establish whether any intervention can be safely evaluated in people.
Kirwan is expected to continue translational diabetes research at the Harold Hamm Diabetes Center, linking laboratory studies with studies involving people. No specific next trial, treatment, or timetable is identified in the supplied report. For now, the study adds a candidate mechanism to investigate and does not change the status of Miro1 from a research target to a clinical option.
muscle energy production supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is Miro1?
Miro1, short for Mitochondrial Rho GTPase 1, is a protein on the outer membrane of mitochondria, which produce energy inside cells. The study examined its role in skeletal muscle and insulin response.
What did the researchers find?
The study linked increased muscle Miro1 with impaired response to insulin. Removing the protein restored that response in preclinical models; in a human exercise group, Miro1 levels fell alongside improvements in insulin sensitivity and muscle energy production.
Does the study establish a new diabetes treatment?
No. The findings identify a potential research target, but the report says more research is needed. It does not show that a Miro1-targeting treatment is safe or effective in people.
Did exercise reduce Miro1 in people with type 2 diabetes?
In the reported randomized trial, participants with obesity and type 2 diabetes assigned to aerobic exercise had lower muscle Miro1 levels, alongside improved insulin sensitivity and muscle energy production. The supplied report does not give the trial’s size or the magnitude of those changes.
Should patients change their diabetes care because of this study?
The study does not provide a basis for changing treatment. Anyone considering a change to diabetes care should discuss it with a qualified health professional.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
